Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07217015 · ClinicalTrials.gov registry record · Phase 2

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

A Phase 2 study of Atopic Dermatitis, sponsored by Kymera Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
200
Enrollment target
20
Study locations

NCT07217015 is a Phase 2 study of Atopic Dermatitis that is actively recruiting participants, run by Kymera Therapeutics. The registered enrollment target is 200 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07217015, a Phase 2 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Kymera Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
200 participants
Enrollment target
20
Study locations

Study Summary

This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema. The main goals of this study are to learn how effective KT-621 is at reducing the severity and extent of AD, the safety and tolerability of KT-621, how KT-621 behaves in the body, and how the body responds to KT-621. This is a 16-week double-blind, placebo-controlled study with a 52-week open-label period.

Conditions Studied

Atopic Dermatitis

Interventions

  • OTHER Placebo
  • DRUG KT-621

Study Locations (20)

California

  • Kymera Investigative Site - Freemont
  • Kymera Investigative Site - Los Angeles
  • Kymera Investigative Site - Santa Monica

Florida

  • Kymera Investigative Site - Delray Beach
  • Kymera Investigative Site - Miami
  • Kymera Investigative Site - Miramar

Michigan

  • Kymera Investigative Site - Ann Arbor
  • Kymera Investigative Site - Detroit

Texas

  • Kymera Investigative Site - San Antonio
  • Kymera Investigative Site - San Antonio

New South Wales

  • Kymera Investigative Site - Darlinghurst
  • Kymera Investigative Site - Kogarah

Alabama

  • Kymera Investigative Site - Birmingham

Arkansas

  • Kymera Investigative Site - North Little Rock

Illinois

  • Kymera Investigative Site - Normal

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-11-24
Est. Completion 2028-06
Phase Phase 2

Sponsor

Kymera Therapeutics

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07217015

The ClinicalTrials.gov registry entry for NCT07217015 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (67% lower). The listed sponsor is Kymera Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07217015 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Michigan.

Frequently Asked Questions

What is clinical trial NCT07217015 about?

NCT07217015 is a clinical study titled "A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis". This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema. The main goals of this study are to learn how effective KT-621 is at reducing the severity and extent of AD, the...

What is the current status of trial NCT07217015?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-11-24. Estimated completion is 2028-06.

What conditions does trial NCT07217015 study?

This clinical trial studies the following conditions: Atopic Dermatitis.

What interventions are being tested in trial NCT07217015?

The interventions under investigation include: Placebo (OTHER), KT-621 (DRUG).

Who is sponsoring clinical trial NCT07217015?

This trial is sponsored by Kymera Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07217015 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atopic Dermatitis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.